Onkologie 2022: 16(Suppl.B): 57-60 | DOI: 10.36290/xon.2022.056

Necrobiotic xanthogranuloma and monoclonal gammopathy

MUDr. Viera Sandecká, Ph.D.
Interní hematologická a onkologická klinika, LF MU a FN Brno

Necrobiotic xanthogranuloma is a progressive and destructive disease associated with paraproteinemia, multiple organ involvement, and an increased risk of developing lymphoproliferative malignancy, such as multiple myeloma, chronic lymphocytic leukemia, or Hodgkin and non-Hodgkin lymphoma. The present article describes a complicated case of a female patient diagnosed with multiple myeloma and necrobiotic xanthogranuloma whose serious health complications were not typical for the diagnosis of multiple myeloma. A thorough diagnostic algorithm and multidisciplinary cooperation of various experts led to the definitive diagnosis. The article also includes a description of the treatment strategy using combination therapy of daratumumab plus lenalidomide and dexamethasone with intravenous administration of immunoglobulins.

Keywords: mnohočetný myelom, nekrobiotický xantogranulom, monoklonální protein, monoklonální gamapatie.

Accepted: October 4, 2022; Published: October 14, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sandecká V. Necrobiotic xanthogranuloma and monoclonal gammopathy. Onkologie. 2022;16(Suppl. B - Monoklonální gamapatie):57-60. doi: 10.36290/xon.2022.056.
Download citation

References

  1. Kyle RA, Rajkumar V. Monoclonal gammopathies of undetermined significance. Myeloma. London: Martin Dunitz Ltd. 2002:415-432.
  2. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:538-548. Go to original source... Go to PubMed...
  3. Rajkumar SV. CME Information: Multiple Myeloma: 2016 update on diagnosis, risk-factors and management. Am J Hematol. 2016;91:719-734. Go to original source... Go to PubMed...
  4. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113:5412-5417. Go to original source... Go to PubMed...
  5. Zahradová L, Adam Z, Feit J, et al. Nekrobiotický xantogranulom - vzácná kožní komplikace u nemocného s mnohočetným myelomem. Vnitřní lékařství. 2010;56(Supplementum 2):179-182.
  6. Fermand JP, Bridoux F, Dispenzieri A, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132(14):1478-1485. Go to original source... Go to PubMed...
  7. Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. Blood. 2018;131(2):163-173. doi:10.1182/blood-2017-09-807560. Go to original source... Go to PubMed...
  8. Dispenzieri A. Monoclonal gammopathies of clinical significance Hematology Am Soc Hematol Educ Program. 2020;(1):380-388. doi: 10.1182/hematology.2020000122. Go to original source... Go to PubMed...
  9. Kossard S, Winkelmann RK. Necrobiotic xanthogranuloma with paraproteinemia. J Am Acad Dermatol. 1980;3(3):257-270. doi: 10.1016/s0190-9622(80)80189-7. PMID: 7451693. Go to original source... Go to PubMed...
  10. Kossard S, Winkelmann RK. Necrobiotic xanthogranuloma. Australas J Dermatol. 1980;21(2):85-88. doi: 10.1111/j.1440-0960.1980.tb00148.x. PMID: 7447815. Go to original source... Go to PubMed...
  11. Szalat R, Arnulf B, Karlin L, et al. Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy. Blood. 2011;118(14):3777-3784. doi: 10.1182/blood-2011-05-356907. Epub 2011 Jul 14. PMID: 21757618. Go to original source... Go to PubMed...
  12. Finan MC, Winkelmann RK. Necrobiotic xanthogranuloma with paraproteinemia. A review of 22 cases. Medicine (Baltimore). 1986;65(6):376-388. doi: 10.1097/00005792-198611000-00003. PMID: 3097454. Go to original source... Go to PubMed...
  13. Spicknall KE, Mehregan DA. Necrobiotic xanthogranuloma. Int J Dermatol. 2009 Jan;48(1):1-10. doi: 10.1111/j.1365-4632.2009.03912.x. PMID: 19126043. Go to original source... Go to PubMed...
  14. Miguel D, Lukacs J, Illing T, Elsner P. Treatment of necrobiotic xanthogranuloma - a systematic review. J Eur Acad Dermatol Venereol. 2017;31(2):221-235. doi: 10.1111/jdv.13786. Epub 2016 Jul 19. PMID: 27436448. Go to original source... Go to PubMed...
  15. Steinhelfer L, Kühnel T, Jägle H, et al. Systemic therapy of necrobiotic xanthogranuloma: a systematic review. Orphanet J Rare Dis. 2022;17(1):132. doi: 10.1186/s13023-022-02291-z. Go to original source... Go to PubMed...
  16. Nelson CA, Zhong CS, Hashemi DA, et al. A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria. JAMA Dermatol. 2020;156(3):270-279. doi: 10.1001/jamadermatol.2019.4221. Go to original source... Go to PubMed...
  17. Adam Z, Pour, L, Řehák Z, et al. FDG-PET/CT dokumentované vymizení nekrobiotického xantogranulomu při potlačení tvorby monoklonálního imunoglobulinu bortezomibem, lenalidomidem a dexametazonem : Popis případu a přehled literatury o léčbě nekrobiotického xantogranulomu. Vnitř lek. 2021;67(6):352-356. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.